Drug Profile

ADEL Y03

Alternative Names: ADEL-Y03

Latest Information Update: 11 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ADEL
Class Anti-inflammatories; Antibodies; Antidementias; Antifibrotics; Antineoplastics
Mechanism of Action Beta globulin modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Preclinical Alzheimer's disease; Cancer; Hepatic fibrosis; Inflammation; Pulmonary fibrosis; Renal fibrosis

11 Dec 2023 Preclinical trials in Alzheimer's disease in South Korea (Parenteral), prior to December 2023 (ADEL pipeline, December 2023)
11 Dec 2023 Preclinical trials in Cancer in South Korea (Parenteral), prior to December 2023 (ADEL pipeline, December 2023)
11 Dec 2023 Preclinical trials in Hepatic fibrosis in South Korea (Parenteral), prior to December 2023 (ADEL pipeline, December 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com